Goo Kelli, Uy Rosalynda, Roswarski Joseph
1 The Daniel K. Inouye College of Pharmacy, University of Hawai`i at Hilo, USA.
2 Tripler Army Medical Center, Honolulu, USA.
J Oncol Pharm Pract. 2019 Jul;25(5):1248-1252. doi: 10.1177/1078155218784762. Epub 2018 Jun 22.
Azacitidine, a deoxyribonucleic acid hypomethylating agent, is used in the treatment of myelodysplastic syndrome. Common adverse effects of azacitidine include bone marrow suppression, injection site reactions, nausea, vomiting, diarrhea, and fatigue. This report focuses on pleuropericardial effusions, an infrequently reported and potentially reversible adverse effect of azacitidine. In this case report, pleuropericardial effusion manifested as the sole radiographic finding in the evaluation of cough occurring during the eighth cycle of treatment with azacitidine. Symptoms and radiographic abnormalities resolved with corticosteroids and diuretics, and the patient could continue with therapy.
阿扎胞苷是一种脱氧核糖核酸去甲基化剂，用于治疗骨髓增生异常综合征。阿扎胞苷的常见不良反应包括骨髓抑制、注射部位反应、恶心、呕吐、腹泻和疲劳。本报告重点关注胸膜心包积液，这是阿扎胞苷一种报道较少但可能可逆的不良反应。在本病例报告中，胸膜心包积液是阿扎胞苷治疗第八周期出现咳嗽评估时唯一的影像学表现。症状和影像学异常通过使用皮质类固醇和利尿剂得以缓解，患者可继续接受治疗。
